Prosecution Insights
Prosecution Insights
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.1% | +18.5% |
| LU, CHENG | 1 | 53.7% | +66.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16935679 | BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LU, CHENG | 32d overdue |
| 17224288 | MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE | PUTTLITZ, KARL J | — |
| 16480506 | ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17224288 | MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | — | Pending | Jun 02, 2021 |
| 16935679 | BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LU, CHENG | 1642 | Other | Final Rejection | 32d overdue | Pending | Jul 22, 2020 |
| 16480506 | ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION | PUTTLITZ, KARL J | 1646 | §103 | Final Rejection | — | Pending | Jul 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial